Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab

REFERENCES

• Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15–23
   PubMed Web of Science ®Google Scholar
• O'Connor PW, Goodman A, Willmer-Hulme AJ, et al. Randomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects. Neurology 2004; 62: 2038–2043
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-la for multiple sclerosis. N Engl J Med 2005; 353: 369–374
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2000; 5353: 375–381
   Google Scholar
• Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353: 362–368
   PubMed Web of Science ®Google Scholar
• Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natal izumab—unforeseen consequences. N Engl I Med 2005; 353: 414–416
   PubMed Web of Science ®Google Scholar
• Astrom KE, Mancall EL, Richardson EP, Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958; 81: 93–111
   PubMed Web of Science ®Google Scholar
• Berger JR, Pall L, Lanska D, et al. Progressive multifocal leukoencephalopathy in patients with HIV infection. I Neurovirol 1998; 4: 59–68
   PubMed Web of Science ®Google Scholar
• Brooks BR, Walker DL. Progressive multifocal leukoencephalo-pathy. Neurol Clin 1984; 2: 299–313
   PubMed Web of Science ®Google Scholar
• Whiteman ML, Post MJ, Berger JR, et al. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: Neuroimaging with clinical and pathologic correlation. Radiology 1993; 187: 233–240
   PubMed Web of Science ®Google Scholar
• Safdar A, Rubocki RJ, Horvath JA, et al. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: Impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002; 35: 1250–1257
   PubMed Web of Science ®Google Scholar
• Vendrely A, Bienvenu B, Gasnault J, et al. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencepha-lopathy. Acta Neuropathol (Berl) 2005; 109: 449–455
   PubMed Web of Science ®Google Scholar
• Bernick C, Gregorios JB. Progressive multifocal leukoencephalo-pathy in a patient with acquired immune deficiency syndrome. Arch Neurol 1984; 41: 780–782
   PubMed Web of Science ®Google Scholar
• Miller JR, Barrett RE, Britton CB, et al. Progressive multifocal leukoencephalopathy in a male homosexual with T-cell immune deficiency. N Engl J Med 1982; 307: 1436–1438
   PubMed Web of Science ®Google Scholar
• Snider WD, Simpson DM, Nielsen S, Gold JW, Hetroka CE, Posner JB. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol 1983; 19: 403–18
   Web of Science ®Google Scholar
• Major EO, Amemiya K, Tornatore CS, et al. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 1992; 5: 49–73
   PubMed Web of Science ®Google Scholar
• Holman RC, Janssen RS, Buehler JW, et al. Epidemiology of progressive multifocal leukoencephalopathy in the United States: Analysis of national mortality and AIDS surveillance data. Neurology 1991; 41:1733–1736
   PubMed Web of Science ®Google Scholar
• ZuRhein GM, Chow SM. Particles resembling papovavirions in human cerebral demyelinating disease. Science 1965; 148: 1477–1479
   PubMed Web of Science ®Google Scholar
• Padgett BL, Walker DL, ZuRhein GM, et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoen-cephalopathy. Lancet 1971; 1:1257–1260
   PubMed Web of Science ®Google Scholar
• Khalili K, Del Valle L, Otte J, et al. Human neurotropic polyomavirus, JCV, and its role in carcinogenesis. Oncogene 2003; 22: 5181-5191
   Google Scholar
• Walker DL, Padgett BL. The epidemiology of human polyoma-viruses. In: Sever JL, Madden D, eds. Polyoma viruses and human neurological disease, New York: Alan R. Liss, 1983: pp. 99–106
   Google Scholar
• Brown P, Tsai T, Gajdusek DC. Seroepidemiology of human papovaviruses. Discovery of virgin populations and some unusual patterns of antibody prevalence among remote peoples of the world. Am] Epidemiol 1975; 102: 331–340
   PubMed Web of Science ®Google Scholar
• Caldarelli-Stefano R, Vago L, Omodeo-Zorini E, et al. Detection and typing of JC virus in autopsy brains and extraneural organs of AIDS patients and non-immunocompromised individuals. I Neurovirol 1999; 5: 125–133
   PubMed Web of Science ®Google Scholar
• Monaco MC, Atwood WJ, Gravell M, et al. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: Implications for viral latency. J Virol 1996; 70: 7004–7012
   PubMed Web of Science ®Google Scholar
• Sabath BE, Major EO. Traffic of JC virus from sites of initial infection to the brain: The path to progressive multifocal leukoencephalopathy. J Infect Dis 2002; 186 (Suppl. 2): S180—S186
   Google Scholar
• Monaco MC, Jensen PN, Hou J, et al. Detection of JC virus DNA in human tonsil tissue: Evidence for site of initial viral infection. J Virol 1998; 72: 9918–9923
   PubMed Web of Science ®Google Scholar
• Tornatore C, Berger JR, Houff SA, et al. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol 1992; 31: 454–462
   PubMed Web of Science ®Google Scholar
• Andreoletti L, Lescieux A, Lambert V, et al. Semiquantitative detection of JCV-DNA in peripheral blood leukocytes from HIV-1-infected patients with or without progressive multifocal leukoen-cephalopathy. J Med Virol 2002; 66: 1–7
   PubMed Web of Science ®Google Scholar
• Berger JR, Miller C, Mootoor Y, etal. Are saliva and oropharyngeal secretions a source of JCV infection? Present at the third International Polyomavirus Conference, 2005, Providence, RI, USA
   Google Scholar
• Dubois V, Lafon ME, Ragnaud JM, et al. Detection of JC virus DNA in the peripheral blood leukocytes of HIV-infected patients. AIDS 1996; 10: 353–358
   PubMed Web of Science ®Google Scholar
• Koralnik IJ, Boden D, Mai VX, et al. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 1999; 52: 253–260
   PubMed Web of Science ®Google Scholar
• Weber T, Weber F, Petry H, et al. Immune response in progressive multifocal leukoencephalopathy: An overview. J Neurovirol 2001; 7: 311–317
   PubMed Web of Science ®Google Scholar
• Berger JR. Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: Explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions. J Neurovirol 2003; 9 (Suppl 1.): S38—S41
   Google Scholar
• D'Souza M, Fauci A. Immunopathogenesis. In: Merigan TC, Bartlett JG, Bolognesi D, eds. Textbook of AIDS Medicine, 2nd edn, Baltimore, MA, USA: Williams & Wilkins, 1999: pp. 59-86
   Google Scholar
• Houff SA, Major E0, Katz DA, et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 1988; 318: 301–315
   PubMed Web of Science ®Google Scholar
• Major E0, Amemiya K, Elder G, et al. Glial cells of the human developing brain and B cells of the immune system share a common DNA binding factor for recognition of the regulatory sequences of the human polyomavirus, JCV. J Neurosci Res 1990; 27: 461–471
   PubMed Web of Science ®Google Scholar
• Koralnik IJ, Schmitz JE, Lifton MA, et al. Detection of JC virus DNA in peripheral blood cell subpopulations of HIV-1-infected indivi-duals. J Neurovirol 1999; 5: 430–435
   PubMed Web of Science ®Google Scholar
• Persidsky Y, Zheng J, Miller D, et al. Mononuclear phagocytes mediate blood—brain barrier compromise and neuronal injury during HIV-1-associated dementia. J Leukoc Biol 2000; 68: 413–422
   PubMed Web of Science ®Google Scholar
• Petito CK, Cash KS. Blood—brain barrier abnormalities in the acquired immunodeficiency syndrome: Immunohistochemical localization of serum proteins in postmortem brain. Ann Neurol 1992; 32: 658–666
   PubMed Web of Science ®Google Scholar
• Berger JR, Nath A, Greenberg RN, et al. Cerebrovascular changes in the basal ganglia with HIV dementia. Neurology 2000; 54: 921-926
   Google Scholar
• Nottet HS, Persidsky Y, Sasseville VG, et al. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunol 1996; 156: 1284–1295
   PubMed Web of Science ®Google Scholar
• Berger JR, Chauhan A, Galey D, et al. Epidemiological evidence and molecular basis of interactions between HIV and JC virus. J Neurovirol 2001; 7: 329–338
   PubMed Web of Science ®Google Scholar
• Tada H, Rappaport J, Lashgari M, et al. Trans-activation of the JC virus late promoter by the tat protein of type 1 human immunodeficiency virus in glial cells. Proc Natl Acad Sci USA 1990; 87: 3479–3483
   PubMed Web of Science ®Google Scholar
• Kim SY, Choi EC, Woo Jo Y, et al. Transcriptional activation of JC virus early promoter by phorbol ester and interleukin-1beta: Critical role of nuclear factor-1. Virology 2004; 327: 60–69
   PubMed Web of Science ®Google Scholar
• Enam S, Sweet TM, Amini S, et al. Evidence for involvement of transforming growth factor beta1 signaling pathway in activation of JC virus in human immunodeficiency virus 1-associated progressive multifocal leukoencephalopathy. Arch Pathol Lab Med 2004; 128: 282–291
   PubMed Web of Science ®Google Scholar
• Rudick RA, Sandrock A. Natalizumab: Alpha4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 2004; 4: 571–580
   PubMedGoogle Scholar
• Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999; 53: 466–472
   PubMed Web of Science ®Google Scholar
• Lu TT, Cyster JG. Integrin-mediated long-term B cell retention in the splenic marginal zone. Science 2002; 297: 409–412
   PubMed Web of Science ®Google Scholar
• von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348: 68–72
   PubMed Web of Science ®Google Scholar
• Major EO. JC virus in the CSF and plasma of natalizumab treated patients. In: Paper presented at ECTRIMS, Thessaloniki, Greece:, 2005
   Google Scholar
• Koralnik IJ. Overview of the cellular immunity against JC virus in progressive multifocal I eu koencephal opathy. J Neurovirol 2002; 8 (Suppl. 2): S59—S65
   Google Scholar
• Koralnik IJ, Du Pasquier RA, Letvin NL. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoen-cephalopathy. J Virol 2001; 75: 3483–3487
   PubMed Web of Science ®Google Scholar
• Ferrante P, Omodeo-Zorini E, Caldarelli-Stefano R, et al. Detection of JC virus DNA in cerebrospinal fluid from multiple sclerosis patients. Mult Scler 1998; 4: 49–54
   PubMed Web of Science ®Google Scholar
• Olmos Y, Alvarez-Lafuente R, Garcia-Montojo M, et al. JC virus and multiple sclerosis: A study in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating event. Mult Scler 2005; 11 (Suppl. 1): S133—S134
   Google Scholar
• Bogdanovic G, Priftakis P, Hammarin AL, et al. Detection of JC virus in cerebrospinal fluid (CSF) samples from patients with progressive multifocal leukoencephalopathy but not in CSF samples from patients with herpes simplex encephalitis, enter-oviral meningitis, or multiple sclerosis. J Clin Microbiol 1998; 36: 1137–1138
   PubMed Web of Science ®Google Scholar
• Olsson T, lacobaeus E, Brundin L. JC viral DNA in a cohort of relapsing-remitting multiple sclerosis patients. Mult Scler 2005; 11 (Suppl. 1): S178
   Google Scholar
• Sheridan C. Third Tysabri adverse case hits drug class. Nat Rev Drug Discov 2005; 4: 357–358
   PubMed Web of Science ®Google Scholar